BioCryst Pharma (BCRX) Tops Q1 EPS by 7c ; Offers Guidance
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $9.14 +1.67%
Revenue Growth %: +13.7%
Financial Fact:
Total expenses: 17M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Revenue Growth %: +13.7%
Financial Fact:
Total expenses: 17M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
BioCryst Pharma (NASDAQ: BCRX) reported Q1 EPS of $0.00, $0.07 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $134.2 million versus the consensus estimate of $127.91 million.
GUIDANCE:
BioCryst Pharma sees FY2025 revenue of $580-600 million, versus the consensus of $563.6 million.
For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Primoris cuts 2026 outlook on renewables cost overruns, COO exits
- Qualcomm (QCOM) PT Raised to $195 at BofA Securities
- A.O. Smith executive chairman to retire, CEO to assume chairman role
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
